Definitive chemoradiotherapy for locoregional recurrence of esophageal squamous cell carcinoma patients after radical surgery: Retrospective study.

Authors

null

Kentaro Harada

Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Kentaro Harada , Shun Yamamoto , Akihiro Ohara , Mai Itoyama , Yoshitaka Honma , Tairo Kashihara , Koji Inaba , Koshiro Ishiyama , Junya Oguma , Hiroshi Igaki , Hiroyuki Daiko , Ken Kato

Organizations

Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital, Chuo-Ku, Japan, Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan, Department of Head and Neck Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Research Funding

No funding received

Background: The prognosis of esophageal squamous cell carcinoma (ESCC) patients with recurrence after radical surgery remains poor, with a median overall survival (OS) of 5-10 months. Locoregional recurrence (LR) have a potential to cure by definitive chemoradiotherapy (dCRT) or surgery. However, there are a few data on clinical outcomes of the patients with LR. We evaluated the efficacy and safety of dCRT for LR after radical surgery retrospectively. Methods: The subjects who had LR after surgery were corrected from medical record between January 2015 and April 2020 in our hospital. LR was defined as recurrence within the regional and supraclavicular lymph nodes after curative surgery. CRT consist of fluoropyrimidine and platinum with radiation at a dose of 50.4-60Gy. Complete response (CR) rate, progression-free survival (PFS), OS, and safety was evaluated. Results: Twenty-five patients who had LR after surgery were analyzed with the median follow-up time of 21.5 (range: 0.47-60.2) months. Patients’ characteristics at the initiation of dCRT were as follows; median age (range): 70 (40-70) years old, male/female: 20 (80%)/5 (20%) patients, PS 0/1/2: 11 (44%)/12 (48%)/ 2 (8%) patients. Chemotherapy regimens were cisplatin and 5-fluorouracil in 23 (92%) patients, nedaplatin and 5-fluorouracil in 1 (4%) patient, and S-1 in 1 (4%) patient. Radiation doses were 60 Gy in 24 (96%) patients and 50.4 Gy in 1 (4%) patient. CR was achieved in 13 (53%) patients. The median PFS was 9.7 (95%CI: 5.6-NA) months, and the median OS was 28.8 (95%CI: 21.2-NA) months. The one-year survival rate was 78.7 (95%CI: 56.1-90.6) % and the three-years survival rate was 25.9 (95%CI: 5.1-54.1) %. Grade 3 or higher adverse events were observed in 3 (12%) patients of neutropenia, in 3 (12%) patients of leukopenia, and in 2 (8%) patients of febrile neutropenia. Treatment-related death due to febrile neutropenia was observed in 1 (4%) patient. No patient presented with severe late toxicity after dCRT. Conclusions: In this study, dCRT for LR after surgery was tolerable and promising efficacy with curative intent.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

DOI

10.1200/JCO.2022.40.4_suppl.314

Abstract #

314

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts